Ultragenyx's gene therapy helps control ammonia levels in late-stage study

March 12 (Reuters) - Ultragenyx Pharmaceutical said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder ...

Ultragenyx's gene therapy study shows ammonia reduction in rare metabolic disorder

Ultragenyx Pharmaceutical Inc. RARE shares are down on Thursday as the company reported data from its Phase 3 study of DTX301 ...
News Medical

High ammonia levels lead to fewer T cells and immunotherapy resistance in colorectal cancer

High levels of ammonia in tumors lead to fewer T cells and immunotherapy resistance in mouse models of colorectal cancer, new findings from the University of Michigan Rogel Cancer Center revealed.
Science Daily

Eating less protein may slow liver cancer growth, study finds

A Rutgers-led study found that eating less protein may help slow liver cancer in people with impaired liver function. When ...

Ultragenyx posts late-stage trial win for gene therapy in urea cycle disorder

Ultragenyx Pharma (RARE) stock is in focus as gene therapy DTX301 met its main goal in a late-stage trial for the most common ...